Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective

Bradley M Sugden; Sabine E Grimm; Robert Wolff; Nigel Armstrong; Thomas Otten; Teebah Abu-Zahra; Mark Perry; Mubarak Patel; Jiongyu Chen; Caro Noake; Manuela Joore; Willem J A Witlox

doi:10.1007/s40273-024-01381-z

Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective

Bradley M Sugden
, Sabine E Grimm
, Robert Wolff
, Nigel Armstrong
, Thomas Otten
, Teebah Abu-Zahra
, Mark Perry
, Mubarak Patel
, Jiongyu Chen
, Caro Noake
, Manuela Joore
, Willem J A Witlox

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	615-618
Number of pages	4
Journal	Pharmacoeconomics
Volume	42
Issue number	6
Early online date	7 May 2024
DOIs	https://doi.org/10.1007/s40273-024-01381-z
Publication status	Published - 1 Jun 2024

Bibliographical note

Keywords

Humans
Antibodies, Monoclonal, Humanized/therapeutic use
Bayes Theorem
Neoplasms/drug therapy
Technology Assessment, Biomedical
Antineoplastic Agents, Immunological/therapeutic use
Cost-Benefit Analysis

Access to Document

10.1007/s40273-024-01381-zLicence: CC BY-NC

Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective
© The Author(s) 2024
Final published version, 566 KBLicence: CC BY-NC

Cite this

Sugden, B. M., Grimm, S. E., Wolff, R., Armstrong, N., Otten, T., Abu-Zahra, T., Perry, M., Patel, M., Chen, J., Noake, C., Joore, M., & Witlox, W. J. A. (2024). Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective. Pharmacoeconomics, 42(6), 615-618. https://doi.org/10.1007/s40273-024-01381-z

@article{73333e28484e4574b77302bb92ac663e,

title = "Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective",

keywords = "Humans, Antibodies, Monoclonal, Humanized/therapeutic use, Bayes Theorem, Neoplasms/drug therapy, Technology Assessment, Biomedical, Antineoplastic Agents, Immunological/therapeutic use, Cost-Benefit Analysis",

author = "Sugden, \{Bradley M\} and Grimm, \{Sabine E\} and Robert Wolff and Nigel Armstrong and Thomas Otten and Teebah Abu-Zahra and Mark Perry and Mubarak Patel and Jiongyu Chen and Caro Noake and Manuela Joore and Witlox, \{Willem J A\}",

note = "{\textcopyright} The Author(s) 2024",

year = "2024",

month = jun,

day = "1",

doi = "10.1007/s40273-024-01381-z",

language = "English",

volume = "42",

pages = "615--618",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis",

number = "6",

}

Sugden, BM, Grimm, SE, Wolff, R, Armstrong, N, Otten, T, Abu-Zahra, T, Perry, M, Patel, M, Chen, J, Noake, C, Joore, M & Witlox, WJA 2024, 'Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective', Pharmacoeconomics, vol. 42, no. 6, pp. 615-618. https://doi.org/10.1007/s40273-024-01381-z

Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective. / Sugden, Bradley M; Grimm, Sabine E; Wolff, Robert et al.
In: Pharmacoeconomics, Vol. 42, No. 6, 01.06.2024, p. 615-618.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR

T2 - External Assessment Group Perspective

AU - Sugden, Bradley M

AU - Grimm, Sabine E

AU - Wolff, Robert

AU - Armstrong, Nigel

AU - Otten, Thomas

AU - Abu-Zahra, Teebah

AU - Perry, Mark

AU - Patel, Mubarak

AU - Chen, Jiongyu

AU - Noake, Caro

AU - Joore, Manuela

AU - Witlox, Willem J A

PY - 2024/6/1

Y1 - 2024/6/1

KW - Humans

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Bayes Theorem

KW - Neoplasms/drug therapy

KW - Technology Assessment, Biomedical

KW - Antineoplastic Agents, Immunological/therapeutic use

KW - Cost-Benefit Analysis

U2 - 10.1007/s40273-024-01381-z

DO - 10.1007/s40273-024-01381-z

M3 - Article

C2 - 38713424

SN - 1170-7690

VL - 42

SP - 615

EP - 618

JO - Pharmacoeconomics

JF - Pharmacoeconomics

IS - 6

ER -

Sugden BM, Grimm SE, Wolff R, Armstrong N, Otten T, Abu-Zahra T et al. Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective. Pharmacoeconomics. 2024 Jun 1;42(6):615-618. Epub 2024 May 7. doi: 10.1007/s40273-024-01381-z